source
- STAT+: FDA wants to exclude weight loss drugs from a compounding listFDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.STAT · 3mo ago↗ source
- STAT+: Five-way obesity drug is super effective — in miceA 'quintuple agonist,' Alector halts it Alzheimer's trial, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- STAT+: DOJ, Elevance spar over access to top exec in Medicare Advantage fraud caseElevance said a top exec would depart, days after the Justice Department asked to depose him.STAT · 3mo ago↗ source